To include your compound in the COVID-19 Resource Center, submit it here.

MediGene: Paring back in the clinic

Having headed Ribozyme Pharmaceuticals Inc. for a year, CEO Howard Robin now hopes to broaden its focus beyond ribozymes to include more applications of nucleic acid chemistry, such as diagnostics, manufacturing and its RNAi gene-silencing technology. The company also has cut some clinical programs in favor of second generation molecules with improved stability and

Read the full 549 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers